Magnetic resonance angiography (MRA) in renally impaired patients: When and how

European Journal of Radiology

Volumn 66, Issue 2, 2008, Pages 213-219

  Bongartz, Georg ^a   Mayr, Michael ^a   Bilecen, Deniz ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Gadolinium; Magnetic resonance angiography; Nephrogenic systemic fibrosis

Indexed keywords

AGENTS; DISEASES; GADOLINIUM; MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATIENT TREATMENT;

BLOOD POOL AGENTS; MAGNETIC RESONANCE ANGIOGRAPHY; NEPHROGENIC SYSTEMIC FIBROSIS;

ANGIOGRAPHY;

CONTRAST MEDIUM; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; IODINATED CONTRAST MEDIUM;

ARTICLE; CHRONIC KIDNEY DISEASE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTRAST ENHANCEMENT; DIGITAL SUBTRACTION ANGIOGRAPHY; DOSE RESPONSE; DRUG MEGADOSE; HUMAN; IMAGE QUALITY; KIDNEY DISEASE; KIDNEY DYSFUNCTION; MAGNETIC RESONANCE ANGIOGRAPHY; NEPHROGENIC FIBROSING DERMOPATHY; PRIORITY JOURNAL;

CONTRAST MEDIA; DECISION MAKING; FIBROSIS; GADOLINIUM; HUMANS; KIDNEY DISEASES; MAGNETIC RESONANCE ANGIOGRAPHY; SKIN DISEASES;

EID: 43049143825     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejrad.2008.01.031     Document Type: Article

References (26)

1. Loeffler W., and Laub G. Magnetic resonance angiography. Can Assoc Radiol J 41 1 (1990) 19-23
2. Price R.R., Creasy J.L., Lorenz C.H., and Partain C.L. Magnetic resonance angiography techniques. Invest Radiol 27 Suppl. 2 (1992) 27-32
3. Boos M., Scheffler K., Ott H.W., Radü E.W., and Bongartz G. Conventional magnetic resonance angiography and contrast enhanced magnetic resonance angiography of extracranial blood vessel segments. Radiologe 37 7 (1997) 515-528
4. Ozsarlak O., Van Goethem J.W., Maes M., and Parizel P.M. MR angiography of the intracranial vessels: technical aspects and clinical applications. Neuroradiology 46 12 (2004) 955-972
5. Prince M.R. Contrast-enhanced MR angiography: theory and optimization. Magn Reson Imag Clin N Am 6 2 (1998) 257-267
6. Saloner D. Determinants of image appearance in contrast-enhanced magnetic resonance angiography. A review. Invest Radiol 33 9 (1998) 488-495
7. Schoenberg S.O., Knopp M.V., Prince M.R., Londy F., and Knopp M.A. Arterial-phase three-dimensional gadolinium magnetic resonance angiography of the renal arteries. Strategies for timing and contrast media injection. Invest Radiol 33 9 (1998) 506-514
8. Wang Y., Lee H.M., Avakian R., Winchester P.A., Khilnani N.M., and Trost D. Timing algorithm for bolus chase MR digital subtraction angiography. Magn Reson Med 39 5 (1998) 691-696
9. Ho V.B., Choyke P.L., Foo T.K., et al. Automated bolus chase peripheral MR angiography: initial practical experiences and future directions of this work-in-progress. J Magn Reson Imag 10 3 (1999) 376-388
10. Levey A.S., Coresh J., Balk E., et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139 2 (2003) 137-147
11. Prince M.R., Arnoldus C., and Frisoli J.K. Nephrotoxicity of high-dose gadolinium compared with iodinated contrast. J Magn Reson Imag 6 (1996) 162-166
12. Rieger J., Sitter T., Toepfer M., Linsenmaier U., Pfeifer K.J., and Schiffl H. Gadolinium as an alternative contrast agent for diagnostic and interventional angiographic procedures in patients with impaired renal function. Nephrol Dial Transplant 17 5 (2002) 824-828
13. Thomsen H.S., et al. Gadolinium-containing contrast media for radiographic examinations: a position paper. Eur Radiol 12 10 (2002) 2600-2605
14. Bongartz G. Imaging in the time of NFD/NSF: do we have to change our routines concerning renal insufficiency?. Magn Reson Mater Phys 20 2 (2007) 57-62
15. Elmståhl B., Leander P., Grant D., et al. Histomorphological changes after renal X-ray arteriography using iodine and gadolinium contrast media in an ischemic porcine model. Acta Radiol 23 (2007) 1-11
16. Sam II A.D., Morasch M.D., Collins J., Song G., Chen R., and Pereles F.S. Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. J Vasc Surg 38 2 (2003) 313-318
17. Trani C., Burzotta F., Biondi-Zoccai G.G., et al. Use of a novel high-osmolar gadolinium chelate, gadobutrol, for percutaneous renal artery stenting in two patients with chronic renal failure. Int J Cardiol 102 2 (2005) 361-362
18. Briguori C., Colombo A., Airoldi F., et al. Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures. Catheter Cardiovasc Interv 67 2 (2006) 175-180
19. Esteban J.M., Alonso A., Cervera V., and Martínez V. One-molar gadolinium chelate (gadobutrol) as a contrast agent for CT angiography of the thoracic and abdominal aorta. Eur Radiol 17 9 (2007) 2394-2400
20. Cowper S.E., Robin H.S., Steinberg S.M., Su L.D., Gupta S., and LeBoit P. Scleromyxoedema-like cutaneous diseases in renal dialysis patients. Lancet 356 (2000) 1000-1001
21. Weinreb J.C. MRA, CTA VIE for vascular imaging prominence. Proceedings of the 24th Annual Course of the Society of Computed Body Tomography and Magnetic Resonance (SCBT/MR). Miami, Florida, March 19-23 (2001). http://www.medscape.com/viewarticle/420136
22. Planken R.N., Tordoir J.H., Dammers R., et al. Stenosis detection in forearm hemodialysis arteriovenous fistulae by multiphase contrast-enhanced magnetic resonance angiography: preliminary experience. J Magn Reson Imag 17 1 (2003) 54-64
23. Sadowski E.A., Bennett L.K., Chan M.R., Wentland A.L., Garrett A.l., and Djamali A. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243 (2007) 148-157
24. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant 21 (2006) 1104-1108
25. Zhang H., Morris M., MacGregor J., et al. Incidence of NSF at Columbia and Cornell Universities. Presented at MR Angio Club Meeting. Istambul, October 3-5 (2007)
26. Parmelee D.J., Walovitch R.C., Ouellet H.S., and Lauffer R.B. Preclinical evaluation of the pharmacokinetics, biodistribution and elimination of MS-325, a blood pool agent for MRI. Invest Rad 32 12 (1997) 741-747